Wisconsin is currently home to 1284 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Milwaukee, Madison, Green Bay and Marshfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Use of Sensory Substitution to Improve Arm Control After Stroke
NCT03298243
Recruiting
Supplementing or augmenting sensory information to those who have lost proprioception after stroke could help improve functional control of the arm. Thirty subjects will be recruited to a single site to evaluate the ability of supplemental kinesthetic feedback (a form of vibrotactile stimulation) to improve motor function. Participants will be tested in performing reaching movements as well as more functional tasks such as simulated drinking from a glass
Gender:
ALL
Ages:
21 years and above
Trial Updated:
05/28/2024
Locations: Marquette University, Milwaukee, Wisconsin
Conditions: Stroke, Proprioceptive Disorders
Register for Updates
A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma
NCT05757102
Recruiting
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
05/24/2024
Locations: GSK Investigational Site, Milwaukee, Wisconsin
Conditions: Asthma
Register for Updates
Auricular Vagal Nerve Stimulation for Hypermobile Ehlers-Danlos Syndrome
NCT05212129
Recruiting
Hypermobile Ehlers-Danlos Syndrome (hEDS) is a connective tissue disorder characterized by hyperextensible skin, joint hypermobility and additional connective tissue manifestations. For unclear reasons, hEDS is associated with many gastrointestinal (GI) and autonomic nervous system (ANS) complaints such as postural orthostatic tachycardia syndrome (POTS). This study will address the clinical relationship between hEDS/Hypermobile Spectrum Disorders and autonomic regulation and see if there is a b... Read More
Gender:
ALL
Ages:
Between 10 years and 18 years
Trial Updated:
05/23/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Functional Gastrointestinal Disorders, Hypermobile Ehlers-Danlos Syndrome, Postural Orthostatic Tachycardia Syndrome, Autonomic Nervous System Disease, Autonomic Nervous System Imbalance
Register for Updates
Parent-Level Predictors of Early Language Interaction Quality and Intervention Outcomes
NCT03525951
Recruiting
Children with poor early language skills are at risk for academic, social, vocational, and health difficulties across the lifespan. Parent training-as part of early language intervention-is a cost-effective option to address this public health issue, but these interventions demonstrate large individual differences in outcomes and barriers to scalability. The purpose of this research is to examine parent-level predictors of early language interaction quality and modifiability during training, whi... Read More
Gender:
ALL
Ages:
30 months and above
Trial Updated:
05/23/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Language Development Disorders, Autism Spectrum Disorder
Register for Updates
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
NCT04904588
Recruiting
This is a prospective, multi-center, Phase II study of hematopoietic cell transplantation (HCT) using human leukocyte antigen (HLA)-mismatched unrelated donors (MMUD) for peripheral blood stem cell transplant in adults and bone marrow stem cell transplant in children. Post-transplant cyclophosphamide (PTCy), tacrolimus and mycophenolate mofetil (MMF) will be used for for graft versus host disease (GVHD) prophylaxis. This trial will study how well this treatment works in patients with hematologic... Read More
Gender:
ALL
Ages:
1 year and above
Trial Updated:
05/22/2024
Locations: University of Wisconsin Hospital and Clinic, Madison, Wisconsin
Conditions: Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
Register for Updates
Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block
NCT04559425
Recruiting
Few studies are specifically designed to address health concerns that are already relevant during pregnancy. The consequence is a lack of evidence on best clinical practice. This includes mothers and their babies when pregnancy is complicated by an abnormally slow heart rate due to maternal antibody-mediated heart disease in the unborn baby (fetus). Since the late seventies, it has been possible to detect and monitor fetal disease by ultrasound images and to treat selected conditions with pharma... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Heart Block Complete, Heart Block Second Degree
Register for Updates
Prospective Observational Cohort Study of Fetal Atrial Flutter & Supraventricular Tachycardia
NCT03376438
Recruiting
The FAST Trial Registry is a prospective observational cohort study of fetuses with a new diagnosis of atrial flutter (AF) or supraventricular tachycardia (SVT) that is severe enough to consider prenatal treatment (see eligibility criteria below). Aims of the Registry include to establish a large clinical database to determine and compare the efficacy and safety of different prenatal treatment strategies including observation without immediate treatment, transplacental antiarrhythmic fetal treat... Read More
Gender:
FEMALE
Ages:
Between 16 years and 50 years
Trial Updated:
05/21/2024
Locations: Children's Hospital of Wisconsin, Milwaukee, Wisconsin
Conditions: Atrial Flutter, Tachycardia, Supraventricular, Tachycardia, Atrial Ectopic, Tachycardia, Reciprocating, Tachycardia Atrial, Tachycardia, Atrioventricular Nodal Reentry, Tachycardia, Paroxysmal, Fetal Hydrops
Register for Updates
PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes
NCT05390892
Recruiting
PRECIDENTD is a randomized, open label, pragmatic clinical trial designed to compare rates of the total number of cardiovascular, kidney, and death events among two alternative treatments for patients with type 2 diabetes (T2D) and either established atherosclerotic cardiovascular disease (ASCVD) or at high risk for ASCVD. To accomplish this objective, we will randomly assign 6,000 patients with established T2D and ASCVD or high-risk for ASCVD in a 1:1 allocation to sodium-glucose cotransporter-... Read More
Gender:
ALL
Ages:
Between 40 years and 80 years
Trial Updated:
05/20/2024
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Type2Diabetes, ASCVD
Register for Updates
High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis
NCT05301101
Recruiting
This trial applies a uniform approach to re-irradiation for planning and diagnostic image fusion, dose summation, dose calculations, and follow up for tumor control and detailed toxicity analysis of serial Organs At Risk (OARs). Serial organs include named arteries and nerves, spinal cord, and gastrointestinal tract.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/20/2024
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Conditions: Solid Tumor
Register for Updates
GCC Agonist Signal in the Small Intestine
NCT05107219
Recruiting
This early phase I trial studies the guanylyl cyclase C (GCC) agonist effect on cGMP signal in duodenal tissue. Plecanatide and linaclotide are drugs approved by the Food and Drug Administration for the treatment of conditions related to constipation. This trial aims to see the effects of taking either one of two drugs, plecanatide or linaclotide, or no drug, on a certain chemical found in the tissue collected from small intestine and how they compare.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/16/2024
Locations: University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin
Conditions: Barrett Esophagus, Gastroesophageal Reflux Disease, Malignant Digestive System Neoplasm
Register for Updates
Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years
NCT04373564
Recruiting
This study is a postmarketing requirement jointly carried out by four NDA holders (Bayer AG, Bracco, GE Healthcare and Guerbet) and the CRO IQVIA. The study aims to create detailed images of the organs and tissue of the human body during x-ray, CT-scan or MRI investigations, doctors are using contrast media (a kind of dye) which can be given to patients by injection into a blood vessel or by mouth. In this study researchers want to find out whether so called gadolinium-based contrast agents (G... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
05/15/2024
Locations: University of Wisconsin, Madison, Wisconsin
Conditions: Motor Function, Cognitive Function, Contrast Media
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
05/14/2024
Locations: University of Wisconsin Hospital and Clinics, Madison, Wisconsin
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates